DIFF Biotech's Innovative Nasal Spray Influenza Vaccine Receives Clinical Trial Approval, Introducing a New Attenuation Pathway Written by PR Newswire Enable JavaScript and cookies to continueRead more http://www.prnasia.com/story/archive/4882436_CN82436_0